Core Viewpoint - The article discusses the advancements and market potential of radiofrequency ablation technology, particularly in the treatment of atrial fibrillation, highlighting the increasing demand driven by an aging population and the introduction of innovative products by Medtronic [1][3][7]. Summary by Sections Atrial Fibrillation and Market Demand - Atrial fibrillation (AF) is a common arrhythmia characterized by rapid and irregular heartbeats, affecting a large patient population. By 2025, the number of AF patients is expected to reach 22.67 million, with a compound annual growth rate (CAGR) of 2.85% from 2021 to 2025, indicating a high demand for surgical interventions [3][4]. Radiofrequency Ablation Overview - Traditional methods such as radiofrequency and cryoablation have become first-line treatments for AF. Radiofrequency ablation is noted for its effectiveness and safety, utilizing high-frequency electromagnetic waves to generate heat that destroys targeted tissue [4][6]. Market Growth and Drivers - The global radiofrequency ablation market was valued at approximately $2 billion in 2019 and is projected to grow to about $4 billion by 2027, with a CAGR of 8.5%. This growth is fueled by technological advancements, broader applications beyond cardiac diseases, and support from governments and healthcare institutions [7][10]. Medtronic's Product Innovations - Medtronic has introduced the PulseSelect system, a pulsed field ablation (PFA) product approved by NMPA, FDA, and CE, which is effective for both paroxysmal and persistent AF. Its design allows for targeted treatment with minimal damage to surrounding tissues [14][15][24]. - The Affera system, another Medtronic product, combines pulsed field and radiofrequency ablation, enhancing the precision and efficiency of cardiac procedures [23][28]. Medtronic Company Overview - Medtronic, established in 1949, is a leading global medical technology company with over 95,000 employees, focusing on chronic disease management across various medical fields. In the fourth fiscal quarter of 2025, the company reported net sales of $8.93 billion, up from $8.59 billion in the previous year [33][34].

Core Viewpoint - The article highlights the advancements in the medical technology sector, particularly focusing on innovative medical devices that have received special review status from the NMPA, indicating a growing trend in the industry towards innovation and regulatory support [1]. Company Summaries - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a leading global medical device supplier, established in 1991, with a revenue of 36.73 billion yuan in 2024, reflecting a 5.1% year-on-year growth, and a net profit of 11.67 billion yuan, up 0.7% [5]. - Wuxi Reiming Vision Technology Co., Ltd. specializes in the research and production of artificial lenses, having developed advanced hydrophobic acrylic materials and received CE certification for its products, indicating its strong R&D capabilities [6]. - Shenzhen Gamma Knife Technology Co., Ltd. has been focused on high-end medical equipment, particularly in radiation therapy, since its establishment in 1993, showcasing its commitment to innovation in the medical technology field [7]. - Suzhou Puno Medical Technology Co., Ltd. is a national high-tech enterprise founded in 2020, dedicated to the development of products related to tumor brachytherapy, emphasizing its strong R&D capabilities and innovative approach [10]. - Hangzhou Aijinglun Technology Co., Ltd. is an innovative ophthalmic medical device company established in 2015, known for its unique suspension-type intraocular lens, which fills a gap in the market for high-degree correction lenses [13]. - Beijing Shanning Kezhi Medical Device Co., Ltd. focuses on biodegradable zinc alloy technology, with products entering clinical trials, showcasing its innovative approach in the biomedical field [15]. - Medtronic, a global leader in medical technology founded in 1949, operates in over 70 disease areas, providing lifelong treatment solutions for chronic disease patients [18]. - Shanghai Yangshan Biotechnology Co., Ltd. was established in 2023, collaborating with top hospitals and dental clinics, indicating its strong market positioning in the dental sector [19]. - Xiamen Shide Medical Equipment Co., Ltd. emphasizes innovation in surgical instruments, having obtained numerous patents and certifications, and is recognized for its diverse product line [20][21]. - Guangzhou Xinhanglu Medical Technology Co., Ltd. focuses on innovative cardiac electrophysiology products, with a unique four-dimensional mapping system that enhances treatment precision [22]. - Shanghai Jinkui Medical Device Co., Ltd. specializes in cardiovascular interventional materials, having developed several pioneering products and maintaining strong R&D partnerships [23]. - Guokexin Medical Technology Co., Ltd. is engaged in the development of advanced medical equipment for boron neutron capture therapy, marking a significant advancement in cancer treatment technology [24]. - Shanghai Ruining Biotechnology Co., Ltd. focuses on high-end biomedical materials, with a strong emphasis on innovation and collaboration with leading cancer treatment centers [25]. - Suzhou Sainasi Medical Technology Co., Ltd. is dedicated to cardiac electrophysiology, providing innovative solutions and a comprehensive product line for the medical field [26].